Growing community of inventors

Beijing, China

Fengping Xiao

Average Co-Inventor Count = 11.19

ph-index = 1

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 3

Fengping XiaoJing Li (5 patents)Fengping XiaoHongjun Wang (5 patents)Fengping XiaoYanping Zhao (5 patents)Fengping XiaoLiying Zhou (5 patents)Fengping XiaoYuanyuan Jiang (5 patents)Fengping XiaoNing Shao (5 patents)Fengping XiaoYeming Wang (5 patents)Fengping XiaoYanan Liu (3 patents)Fengping XiaoGong Li (3 patents)Fengping XiaoHuai Huang (3 patents)Fengping XiaoZhenguang Zou (3 patents)Fengping XiaoKai Liu (2 patents)Fengping XiaoFajie Li (2 patents)Fengping XiaoHongjun Wang (1 patent)Fengping XiaoXiang Li (1 patent)Fengping XiaoFengping Xiao (5 patents)Jing LiJing Li (118 patents)Hongjun WangHongjun Wang (25 patents)Yanping ZhaoYanping Zhao (16 patents)Liying ZhouLiying Zhou (16 patents)Yuanyuan JiangYuanyuan Jiang (13 patents)Ning ShaoNing Shao (7 patents)Yeming WangYeming Wang (6 patents)Yanan LiuYanan Liu (15 patents)Gong LiGong Li (11 patents)Huai HuangHuai Huang (5 patents)Zhenguang ZouZhenguang Zou (4 patents)Kai LiuKai Liu (174 patents)Fajie LiFajie Li (4 patents)Hongjun WangHongjun Wang (7 patents)Xiang LiXiang Li (17 patents)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Beijing Tide Pharmaceutical Co., Ltd. (5 from 17 patents)


5 patents:

1. 12180243 - Receptor inhibitor, pharmaceutical composition comprising same, and use thereof

2. 11919918 - P2X3 andor P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof

3. 11905274 - Receptor inhibitors, pharmaceutical compositions comprising the same and use thereof

4. 11453690 - Receptor inhibitor, pharmaceutical composition comprising same, and use thereof

5. 11414444 - P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/4/2025
Loading…